Ot­su­ka pens AAV deal with Shape Ther­a­peu­tics for eye gene ther­a­pies

Japan­ese phar­ma­ceu­ti­cal com­pa­ny Ot­su­ka has en­list­ed Seat­tle-based RNA edit­ing biotech Shape Ther­a­peu­tics to de­vel­op new ade­no-as­so­ci­at­ed virus (AAV) vec­tors. The hope is to find new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER